Regeneron Pharmaceuticals (NASDAQ:REGN) executives outlined plans for continued growth across its commercial portfolio, upcoming regulatory milestones and pipeline programs during a Wells Fargo investor conference appearance. Ryan Crowe, senior vice president of investor relations and strategic analysis, said the company’s second-quarter financial performance featured double-digit top- and bottom-line growth, supported by commercial execution across EYLEA […]

Regeneron Pharmaceuticals (NASDAQ:REGN) outlined growth opportunities for Dupixent, pipeline catalysts for cemdisiran and continued commercial momentum for EYLEA HD during the Morgan Stanley Global Healthcare Conference. Marion McCourt, Regeneron’s EVP and head of commercial, said Dupixent’s growth opportunity is supported by patient demand across nine approved U.S. indications. While Sanofi independently raised its 2030 Dupixent […]